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Abstract
The effects of the antibacterial peptide PR-39 on nitric oxide (NO) and liver oxygenation (pO2) in a mouse model of endotoxaemia have
been explored. In vivo electron paramagnetic resonance (EPR) spectroscopy was used to make direct measurements of liver NO and pO2.
Measurements of pO2 were made at two different anatomical locations within hepatic tissue to assess effects on blood supply (hence oxygen
supply) and lobule oxygenation; selectively from the liver sinusoids or an average pO2 across the liver lobule. PR-39 induced elevated levels
of liver NO at 6 h following injection of lipopolysaccharide (LPS) as a result of increased iNOS expression in liver, but had no effect on
eNOS or circulatory NO metabolites. Sinusoidal oxygenation was preserved, and pO2 across the hepatic tissue bed improved with PR-39
treatment. We propose that the beneficial effects of PR-39 on liver in this septic model were mediated by increased levels of local NO and
preservation of oxygen supply to the liver sinusoids.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
PR-39, a proline-rich antibacterial peptide was first iden-
tified and isolated in pig intestines [1] and later from
neutrophils [2]. Unlike most antibacterial peptides that kill
bacteria by lysis, PR-39 has been shown to halt protein
and DNA synthesis [3] to work as a neutrophil chemo-
attractant [4] and has also been implicated in wound
repair [5]. Recently, Gao et al. [6] demonstrated PR-39
inhibition of NF-nB-dependent gene expression, suggest-
ing that this antibacterial peptide may have a potential
role during infection and inflammation. Our interest in
PR-39 stems from its potential to inhibit superoxide
production by NADPH oxidase [7] and promote cellular
adaptation to hypoxia [8]. In particular, whether PR-39
could influence NO availability and tissue oxygenation in
septic shock.
Lipopolysaccharide (LPS), a constituent of the Gram-
negative bacterial outer membrane, plays a critical role in
the pathogenesis of septic shock. Although it has long been
recognised that LPS induces a cascade of inflammatory
mediators such as cytokines and reactive oxygen and nitro-
gen species (e.g. superoxide (O2
 ) and nitric oxide (NO))
[9], little is known about the pathophysiological mecha-
nisms underlying the tissue damage that occurs during
multiple organ failure (MOF). Microvascular abnormalities
[10] and inhibition of oxygen utilization [11] are thought to
contribute to this tissue damage, however, the role of excess
NO in relation to these mechanisms and the resulting defects
in tissue oxygenation remain to be elucidated directly in
experimental models of sepsis in vivo.
Conflicting data exists on the putative role of NO during
sepsis. Nitric oxide synthase (NOS) inhibitors have been
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used in animal models of sepsis [12] although investigators
have generally focussed on the preservation of circulatory
haemodynamics, and only limited emphasis has been placed
on whether inhibition of iNOS actually alleviated tissue
damage and improved mortality [13,14]. Contrary to this, it
is becoming increasingly apparent that NO itself may have
protective functions (including maintenance of vascular tone
and neutralising of other reactive oxygen species). Cobb et
al. [15] recently demonstrated that wild-type mice show
improved survival compared with iNOS knockout mice
when subjected to cecal ligation and puncture (CLP). In
addition, the work of Saavedra et al. [16] used a liver-
specific NO donor to reduce LPS-induced liver injury in
mice.
Other oxygen-derived radicals also contribute to local-
ised tissue damage, particularly in liver. Harbrecht et al. [17]
demonstrated that when mice were subjected to NG-mono-
methyl-L-arginine (L-NMMA) and superoxide dismutase
(SOD), the detrimental effects of L-NMMA alone (i.e. lack
of NO) were reduced because SOD eliminated hepatic
damage by superoxide and peroxynitrite. Thus, both circu-
latory and local effects on tissue contribute to eventual
organ failure, and NO, either directly or indirectly plays a
critical role in both. Treatment of any one of these compo-
nents may not necessarily alter eventual survival.
We have previously described direct in vivo measure-
ments of NO and pO2 using electron paramagnetic reso-
nance spectroscopy (EPR) during LPS-induced sepsis [18].
Quantification of liver NO was undertaken using diethyldi-
thiocarbamate (DETC) and iron to complex with NO in the
liver and give rise to a characteristic (EPR) signal. Measure-
ments of pO2 were made using gloxy (an oxygen-sensitive
paramagnetic material [19]). Direct in vivo measurements of
pO2 can also be made at two different anatomical locations
within the liver, either as pO2 specifically from the sinusoids
or as average pO2 across the hepatic tissue bed [20].
The present study was undertaken to explore the effects
of PR-39 in a mouse model of endotoxin (LPS)-induced
sepsis which is well characterized in our laboratory and
provides a haemodynamic model of sepsis over 6 h. We
were specifically interested to evaluate the effects on NO
levels (circulating versus local) and tissue oxygenation. Shi
et al. [7,21] demonstrated increased iNOS expression and
reduced oxidative damage to liver in mice subjected to LPS
challenge. The sepsis model utilised in these studies
involved priming the mice with galactosamine, providing
a liver-specific model in which liver toxicity to LPS is
greatly enhanced and the longer term effects of oxidative
damage to tissue are brought forward. Based on these
results, we hypothesized that PR-39 may influence iNOS
expression directly in the liver as well as inhibit superoxide
production, resulting in increased availability of NO that
might influence liver oxygenation. We report here that PR-
39 increased NO levels locally in liver, preserved sinusoidal
perfusion and oxygenation across the hepatic bed during an
induced septic episode.
2. Materials and methods
2.1. Chemicals
Male Balb/C mice (18–20 g), purchased from Charles
River Laboratories were used throughout. The chemicals
used in these studies were as follows: LPS (isolated from
Escherichia coli, serotype 0111:B4), DETC, ferrous sulfate
(FeSO4) and sodium citrate were all obtained from Sigma
Chemicals Co., St. Louis, USA. PR-39 was synthesised by
the solid-phase method, using t-boc chemistry as previously
described [21]. Gloxy, coal blend was obtained from Filter
Anthracite Ltd., Ammanford, South Wales, UK. Oxygen-
sensitive material was selected as previously described [19].
2.2. Treatment groups
To evaluate the effects of PR-39, LPS and the combined
effects of PR-39 + LPS, mice were assigned to one of the
following treatment groups: (I) LPS 10 mg/ml in saline
(intraperitoneally; 40 mg/kg body weight); (II) PR-39 (4.12
mg/ml in saline; 20.6 mg/kg body weight); (III) co-treat-
ment with LPS and PR-39 (given the same dosage as I and
II); and (IV) a control group of mice injected with pyrogen-
free saline (100 Al). This LPS model is well established in
our laboratory and effectively reproduces a haemodynamic
model of sepsis [18].
2.3. Direct in vivo measurement of NO and pO2 in liver
We have previously demonstrated simultaneous measure-
ment of tissue pO2 and NO in vivo [18]. This is possible
because the EPR signal arising from gloxy and that from the
trapped NO complex have different positions in the mag-
netic field and the resulting EPR spectrum. However, where
the spectral line width reported from Gloxy is broad
(reflecting high tissue pO2), interference in the spectral
signal arising from Gloxy and the trapped NO complex
may result in the inability to accurately measure Gloxy line
width. In the studies reported here, because Gloxy slurry
administered i.v. resided in or close to the liver sinusoids, a
broad spectral line width (i.e. high pO2) was measured. The
pO2 and NO trapping measurements presented in this paper
were therefore conducted on separate animals. Ex vivo
determination of blood levels of NO derivatives, however,
was carried out on animals following EPR oximetry.
2.3.1. In vivo measurements of nitric oxide
The NO trapping agent Fe/DETC was administered by
injecting each mouse with DETC (500 mg/kg, i.p.), immedi-
ately followed by Fe2SO4 and sodium citrate (50 and 250mg/
kg, respectively, subcutaneously, lower leg). This was pre-
pared in a hypoxia chamber (InVivO2 400; Fred Baker
Scientific) so as to minimise the possibility of ferric/DETC
complex formation that might result in spin trapping nitroxyl
anion.
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Fifteen minutes after Fe/DETC administration, the mouse
was anaesthetised with 1.4% isoflurane. The mouse was
restrained in a supine position and then placed inside a
‘‘whole-body’’ resonator of an L-Band EPR spectrometer.
The liver was the area of interest so the upper abdomen of
the mouse was positioned within the active site of the
detecting resonator. EPR spectra were recorded with the
following instrumental settings: 100 G field scan; 60 s scan
time; 0.1 s time constant; 2.0 G modulation. The NO–Fe–
(DETC)2 complex formed gave rise to an EPR triplet signal.
This signal was measured 30 min after Fe/DETC admin-
istration. For each mouse, we observed an initial accumu-
lation of this triplet signal before equilibrium was
established between signal accumulation and decrease.
The latter arising from a combination of EPR signal reduc-
tion, possible cessation of NO synthesis, and clearance of
NO–Fe–(DETC)2 from the tissue. The maximum signal
amplitude at the equilibration point of NO–Fe–(DETC)2
was taken as a level of NO for comparison between mice.
Since DETC/Fe was used to complex with NO in vivo in
these studies, it was important to consider whether DETC/
Fe itself induced changes in the parameters we were
measuring. We have previously demonstrated DETC/Fe
did not have a significant effect on pO2 [18] in a mouse
model of sepsis. Furthermore, administration of DETC/Fe to
control mice did not significantly affect mean arterial blood
pressure or levels of circulating metabolites.
Although nitroxyl anion (NO  ) can react with a related
chelator, methyl–glucamine–dithiocarbamate (MGD) and
recent evidence suggests that NO  is the primary reaction
product of neuronal NOS [22], these recent findings were
obtained in vitro and under conditions where trap concen-
tration was high and NOS/NO production low compared to
our in vivo septic model of iNOS overexpression.
2.3.2. In vivo EPR oximetry
Measurements of partial pressure of oxygen (pO2) were
made using the paramagnetic material gloxy [19]. Gloxy
was administered by one of the two following techniques;
(I) i.v. administration of a fine slurry of gloxy, or (II)
implantation of gloxy particles directly into the liver. His-
tological examination of tissue slices revealed that the slurry
of fine particles injected i.v. distributed mainly to the liver,
and was confined within the hepatic sinusoidal capillaries.
In contrast, the larger gloxy particles injected directly in the
liver apparently localised to the implantation site. Thus,
selective measurements of pO2 were possible at two differ-
ent anatomical locations within hepatic tissue. Measurement
of pO2 by the ‘‘slurry’’ method was used to reflect supply of
oxygen to the sinusoid, whereas ‘‘particle’’ measurements
reflected average pO2 across the liver lobule. The difference
in pO2 between these sites was taken to reflect oxygen
utilization across the liver lobule.
2.3.2.1. Gloxy slurry. One-hundred microliters was admin-
istered intravenously via the lateral tail vein. Slurry was
produced by grinding gloxy using a pestle and mortar,
suspending it in sterile saline, and filtering it through a
20-Am mesh. The mean particle size in the prepared slurry
was found to be 1.1 Am with >80% being smaller than 3 Am.
The distribution and inertness of gloxy slurry administered
i.v. to mice [19] was similar to that found with adminis-
tration of India Ink which distributes almost exclusively to
Kupffer cells of liver [20]. Histological examination of
gloxy slurry in liver shows remarkable homogeneity in
micro-particle size with no apparent affect on cells or
surrounding tissue [23].
2.3.2.2. Gloxy particles. Fifty to two-hundred micro-
meters, chosen manually using a microscope and cell
hemocytometer scale. Mice were anaesthetised with 1.4%
isoflurane and a laparotomy was performed. The particles
were injected using a 22-gauge needle. This contained a
length of wire used to displace the gloxy from the needle
directly into the liver tissue.
Forty-eight hours following administration of gloxy,
baseline pO2 was measured for each mouse using an L-
Band EPR spectrometer with a ‘‘whole-body’’ loop-gap
detecting resonator operating at 1.1 GHz. Typical spectrom-
eter settings were: scan range, 10 G; scan time, 60 s;
modulation amplitude was kept to one-third of the recorded
line width in order to prevent artificial line broadening and
potential over-estimation of pO2. The mice were then
assigned to one of the treatment groups. We focussed our
pO2 studies on 6 h following LPS because this corresponded
with the peak in tissue and circulating NO in this model.
Mice were anaesthetised and placed into the whole-body-
detecting resonator 5 1/2 h after the administration of the
different treatments (as for the measurement of NO). pO2
was calculated by measuring peak-to-peak line width of the
first derivative spectral signal [19]. A 60-s scan time was
used, and spectra were recorded every 3 min for up to a
period of 1 1/2 h. The line width was converted to pO2 by
comparison with a calibration of either gloxy slurry or
particle line width against known O2 tensions. The meas-
ured line width at a given pO2 depends on whether a particle
or slurry is used. The pO2 values reported in this study
reflect true differences in tissue pO2 at specific anatomical
locations, since they were calculated from the appropriate
calibration curve, rather than differences in slurry versus
particle line width or physical properties of the gloxy (such
as size and surface area).
2.3.2.3. Blood flow. An ultrasound flow device (Transonic
systems) was used to monitor blood flow through the
hepatic artery. These measurements were relatively invasive
and extremely sensitive to positioning of the flow probe, we
therefore measured flow in separate groups of mice (i.e.
flow was not measured in animals in which pO2 and NO
measurements were made). We ensured that implantation of
gloxy itself (particles or slurry) had no effect on flow
through the hepatic artery by comparing flow measurements
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in animals with and without prior gloxy implantation.
Typically, in anaesthetised animals, an incision was made
in the upper right peritoneal region. This was large enough
to allow access to the hepatic vessels and placement of the
flow probe. The shaft of the flow probe was 2 mm in
diameter and semi-rigid, and was held in position using a
micro-manipulation device. The incision was closed and
sutured around the probe shaft. Animals were then allowed
to equilibrate for 30 min prior to taking flow readings. We
focussed our studies to taking flow readings every 5 min
between 5.5 and 6.5 h post-saline, LPS, or LPS + PR-39
injection (in order to compare with pO2 and NO measure-
ments). In order to achieve this, surgery to position the flow
probe was initiated 4 h into the septic episode.
2.4. Determination of blood levels of NO derivatives
2.4.1. Measurement of nitrosyl hemoglobin (HbNO)
Binding of NO to deoxyhaemoglobin results in the
formation of nitrosylhemoglobin (HbNO) which can be
measured by EPR spectroscopy [24]. HbNO levels were
determined by cryogenic EPR of a frozen red cell suspen-
sion. Briefly, blood samples were obtained by cardiac
puncture 6 h after treatment. Approximately 500 Al of blood
was collected into an Eppendorf tube containing EDTA.
Blood samples were immediately centrifuged and the
plasma component was removed and stored at  70 jC.
Approximately 150 Al of the red blood cells were then
transferred into a 0.5 ml insulin syringe and immediately
placed into liquid nitrogen. The samples were then stored at
 70 jC until analyzed.
X-band EPR analysis of HbNO was carried out by
placing the samples in an EPR finger dewar containing
liquid nitrogen. Typical instrumental settings were; modu-
lation 4 G; microwave power 10 mW; scan range 200 G, 10
min scan.
2.4.2. Measurement of nitrite and nitrate (NOx)
Nitrite and nitrate concentration was assayed using a
procedure by Misko et al. [25]. Briefly, the plasma samples
were filter-centrifuged (Sartorious Vivaspin 500 mem-
branes) at 10,000 g for 30 min at room temperature.
For total nitrite and nitrate determination, 50 Al of filtrate
was combined with 10 Al of NADPH (10 AM), 40 Al of
phosphate buffer. To determine the amount of nitrate, 50 Al
of filtrate was combined with 10 Al of NADPH (10 AM)
and master mix (equal quantities of glucose-6-phosphate (5
mM), sodium phosphate buffer (14 mM) and nitrate
reductase (0.8 U/ml)). Standards for both nitrite and nitrate
were prepared from the corresponding sodium salt (stand-
ard concentration ranging from 1 to 200 AM). The mixture
was incubated at 37 jC for 1 h. After 1 h incubation, 10 Al
of naphthylethlene diamine (DAN; 0.62 M) was added to
the mixture and was then incubated for a further 10 min at
room temperature. After 10 min incubation, the reaction
was stopped by adding 5 Al of sodium hydroxide (2.8 M).
The fluorescence was read at emission 450 nm and
excitation 365 nm, 10 min following the addition of
sodium hydroxide. Nitrate concentration was calculated
by subtracting the nitrite concentration from the total nitrite




2.5. Measurement of eNOS/iNOS protein expression using
Western blotting
Mice were treated for 6 h and sacrificed following
anaesthetisation with isoflurane. Liver tissues were excised
and were frozen in liquid nitrogen and stored at  80 jC
until tissue extraction.
2.5.1. Preparation of liver extracts
Frozen liver tissue was weighed and homogenized
(Pierce Tissue Grinder Kit) in boiling lysis buffer (10 mM
Tris, pH 7.4, 1.0 mM sodium orthovanadate, 1.0% SDS).
Protein was determined with a Micro Bovine Serum Albu-
min (BSA) Protein Assay Reagent kit (Pierce).
2.5.2. Western blot analysis
Tissue homogenates were heated for 5 min at 95 jC in
cracking buffer (1 ml 2–mercaptoethanol, 2 ml glycerol, 0.4
g SDS, 0.2 g PMSF (100 ), 20 mg bromophenol blue, 20
ml of distilled water). The proteins (40 Ag of protein/lane)
were then separated by SDS-polyacrylamide gel electro-
phoresis (PAGE) in 7.5% resolving gels, and blotted onto
nitrocellulose membranes (Hybond-ECL) in a semi-dry
electrophoretic transfer cell (Trans-Blot; Bio-Rad). Nitro-
cellulose membranes were incubated in blocking solution
(4.5 g NaCl; 0.6 g Tris; 250 Al Tween 20 made up to 500 ml
with distilled water) overnight at room temperature. The
membranes were incubated for 2 h at room temperature with
mouse monoclonal anti-iNOS (N32030, Transduction Lab-
oratories) diluted 1:2500 in blocking solution or rabbit
polyclonal anti-eNOS (Transduction Laboratories) diluted
1:1000 in blocking solution. Thereafter, membranes were
washed five times for 30 min in washing solution (4.5 g
NaCl; 250 Al Tween 20 made up to 500 ml with distilled
water). They were then incubated for 2 h at room temper-
ature with the secondary antibody (rabbit anti-mouse HRP
conjugate (A9044, Sigma)) diluted 1:10,000 in blocking
buffer. The membranes were then washed five times for 30
min in washing buffer and developed using ECL Plus
detection kit (Amersham) according to the protocol supplied
by Amersham. Finally, the chemiluminescence signal was
detected with photographic film (Hyperfilm ECL; Amer-
sham Pharmacia Biotech) and recorded after 5–10 min
exposure.
2.6. Electrophoretic mobility shift assays (EMSAs)
Electrophoretic mobility shift assays (EMSAs) were
used to demonstrate activation and translocation of proteins
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that bind to specific consensus DNA sequences for NF-nB.
Typically, NF-nB activation occurs early following LPS
injection ( < 2 h). Excised samples of liver tissue were snap
frozen in liquid nitrogen. Approximately 50 mg of frozen
tissue was pulverized in a pre-cooled mortar and pestle and
then transferred to a microfuge tube. Cold stop buffer (10
mM Tris–HCl, pH 7.4, 10 mM EDTA, 5 mM EGTA, 100
mM NaF, 200 mM sucrose, 100 AM Na-orthovanadate, 5
mM pyrophosphate, 4 Ag/ml leupeptin, 4 Ag/ml soybean
trypsin inhibitor, 1 mM benzamidine, 20 AM calpain
inhibitor 1, 100 mU/ml aprotinin, and 100 AM phenyl-
methylonylflouride) was added and mixed with the tissue.
The samples were homogenized using 10 strokes in a
dounce homogenizer and then centrifuged at 4000 g.
The resulting cell pellets were rinsed twice and the protein
content of the nuclear extracts was determined using
CoomassieR Plus Reagent (Pierce, Rockford, IL) and
BSA as the standard. Equal amounts (5 Ag) of nuclear
protein was incubated with 5V-[32P] labelled, double-strand
oligonucleotide that contains the consensus binding
sequence for NF-nB (5V-AGTTGAGGGGACTTTCC-
CAGGC-3V) (Promega, Madison, WI). The incubation
mixtures were separated by 4% non-denaturing PAGE
using high ionic conditions and bands were detected by
autoradiography.
2.7. Statistics
Results are expressed as the meanF S.D. of n animals.
Statistical evaluation unless otherwise stated was performed
by one-way analysis of variance (ANOVA) followed by the
Newman–Keuls test for multiple comparison. * *P < 0.001
and *P < 0.01. Statistical analysis was undertaken using
Prism software.
3. Results
3.1. Levels of liver nitric oxide
Liver NO was measured directly in vivo by EPR spec-
troscopy. The resultant NO data from mice in each of the
treatment groups (control, PR-39, LPS, and LPS + PR-39)
are summarised in Fig. 1 and represent NO levels at 1 and 6
h after treatment. There was a significant increase in liver
NO in mice treated with LPS compared with controls at 6 h.
However, mice treated with LPS and PR-39 had signifi-
cantly greater amounts of NO in the liver than those treated
with LPS alone. Mice treated with saline or PR-39 alone
showed similar baseline levels of NO and no significant
change with time.
3.2. Levels of NO-derivatives in blood
We analyzed red blood cells for HbNO (same animals as
in vivo NO above) using ex vivo EPR at liquid nitrogen
temperatures. Mice treated with LPS or LPS and PR-39 had
significantly increased levels of HbNO in the blood com-
pared with control animals. However, unlike the liver NO,
there was no difference between HbNO levels in the LPS or
LPS + PR-39 treated mice. Measurement of plasma nitrite
and nitrate levels (NOx) in these animals showed increased
NOx 6 h following LPS or PR-39 + LPS. Significantly more
NOx was found in the plasma of mice treated with PR-
39 + LPS compared with LPS alone (P < 0.05) (Table 1). As
we have demonstrated previously [28], no significant
increase in NOx was observed 15 min or 1 h after LPS
injection (data not shown).
These results agree with our previous measurements of
NOx and mean arterial blood pressure in control and septic
animals using similar doses of LPS in this model [18]. LPS
(40 mg/kg) typically producing a transient decrease in blood
pressure within minutes following i.p. injection, but large
increases in NOx and severe hypotension at 6 h.
Fig. 1. Direct in vivo measurements of liver NO were made in mice treated
intraperitoneally with saline (control), LPS (40 mg/kg), PR-39 (20.6 mg/kg)
or PR-39 + LPS. NO levels were measured at 1 and 6 h post-treatment
(n>six mice per time point). Data are expressed as meanF S.D. *P= 0.01
for LPS versus PR-39 + LPS and * *P= 0.001 for control versus LPS and
control versus PR-39 +LPS.
Table 1
Summary of the blood flow and NO metabolites in blood from animals in
each of the treatment groups
6 h after treatment
Control LPS PR-39 +LPS PR-39
NOx (Am)
(n= 6)
75.2F 22.0 444.4F 83.9a 582.6F 136.8b 67.4F 16.3
HbNO (AM)
(n= 8)




5.6F 4.0 3.9F 5.7c 4.8F 3.9c 5.1F 4.2c
a Represents a significant difference compared to control group
( P= 0.01).
b Represents significant difference from control, and PR-39 ( P= 0.01),
and also compared to LPS alone ( P= 0.05).
c Represents no significant difference from control group.
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3.3. Expression of NOS protein
NOS protein expression in liver tissue was measured by
Western blot analysis 6 h after treatment. Densitometry was
carried out on NOS bands (n = 5 gels from five mice in each
treatment group). A typical Western blot for eNOS/iNOS
protein expression in livers of control, PR-39, LPS and PR-
39 + LPS treated mice at 6 h is shown in Fig. 2 (A and B,
respectively). The fold difference between PR-39, LPS or
PR-39 + LPS compared with the control group for iNOS
expression was calculated. It was found that iNOS protein
expression was high following both LPS alone and PR-39 +
LPS treatment (P= 0.028 and P= 0.022, respectively, com-
pared to controls). Furthermore, there was a significant
increase following PR-39 + LPS treatment ( P= 0.038).
These results are summarised in Fig. 2(C). There was no
up-regulation of eNOS following treatment (compared with
the positive control in each case).
3.4. Nuclear factor-jB DNA binding
In separate groups of mice, NF-nB DNA binding by
EMSAwas measured at 1, 3 and 5 h post-treatment (Fig. 3).
Mice treated with LPS showed an approximate 18-fold
increase in NF-nB binding at 1 h, typical of early NF-nB
activation following LPS injection. A 14-fold increase was
observed in mice treated with PR-39 + LPS (not signifi-
cantly different from LPS treatment alone). NF-nB binding
declined at 3 and 5 h for both LPS and with PR-39 + LPS.
Both control (saline) and PR-39 showed only baseline NF-
nB binding at all time points.
3.5. Direct in vivo measurements of pO2 at the sinusoids and
across the hepatic tissue bed
Liver pO2 was measured from gloxy EPR line widths at 6
h in mice subjected to saline, LPS, PR-39 and PR-39 + LPS.
Liver pO2 (mm Hg) measured at the sinusoids (from gloxy
slurry) or across the liver lobule (from gloxy particles) is
summarised in Table 2. In control (saline) mice, the mean
pO2 at the sinusoidal lumen was 44.39F 5.13 mm Hg,
whereas average liver lobule pO2 was 4.56F 1.28 mm Hg.
Fig. 2. (A) A representative Western blot for eNOS at 6 h with saline (lane
2), PR-39 (lane 3), LPS (lane 4) and PR-39 + LPS (lane 5). There was no
induction of eNOS protein expression (molecular weight of 140 kDa) found
in any of the treatment groups. Lane 1, positive control from endothelial
cell extract; * denotes non-specific binding. (B) Western blot analysis of
iNOS in liver 6 h after administration of PR-39 +LPS (lane1), LPS (lane 2),
saline (control; lane 3) and PR-39 (lane 4). Each lane contains 40 Ag of
protein from separate animals. (C) Densometric analysis from iNOS bands
of five gels (five animals in each case). * and y—Represent significant
difference from control ( P < 0.03). §—Represents significant difference
from LPS ( P < 0.04).
Fig. 3. NF-nB activity measured in mouse liver. Mice were treated with
saline, LPS or PR-39 + LPS for 1, 3 or 5 h. Each bar represents the mean
valueF S.D. (n= three mice for each time point). * *—Represents a
significant difference where P < 0.001 and §§ represents a significant
difference where P< 0.001.
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The difference in pO2 between these sites was therefore
39.83 mm Hg. When mice were subjected to LPS or PR-
39 + LPS, this pO2 difference was 10.05 and 19.78 mm Hg,
respectively. (Measurements of pO2 in mice subjected to
PR-39 alone are not shown because our initial studies
indicated that PR-39 had no affect upon liver oxygenation).
Treatment with LPS significantly reduced liver pO2 by
approximately 75% at both the sinusoids and across the
lobule tissue (Table 2; LPS). Our data also showed only a
53% decrease in the amount of oxygen being supplied to the
sinusoidal capillaries following PR-39 treatment of LPS
treated mice (reflected by the slurry pO2 in controls com-
pared with PR-39 + LPS). This would indicate that oxygen
supply to liver sinusoids was preserved by PR-39 in septic
animals (Table 2; PR-39 + LPS). There was also a greater
pO2 difference across the liver lobule (pO2 difference (PR-
39 + LPS) = 19.78 mm Hg).
Blood flow through the hepatic artery at 6 h was
essentially the same in control, LPS, and PR-39 + LPS-
treated animals (Table 1). However, we acknowledge the
high degree of variability within the treatment groups and
between individual mice. This factor may have made
measurement of smaller differences in blood flow difficult
to detect.
4. Discussion
Direct measurements of pO2 and NO in vivo are difficult
but are desirable to improve our understanding of organ
dysfunction in sepsis. This study has demonstrated the
usefulness of the EPR technique for the measurement of
these parameters directly in vivo. Measurements of pO2
were made specifically from liver sinusoids (reflecting
supply of blood and oxygen to the liver lobule) and also
as average pO2 across the liver lobule. With this technology,
we have shown that the antibacterial peptide PR-39 can
preserve sinusoid perfusion and oxygen levels across the
hepatic tissue bed in our LPS-induced model of septic
shock. Furthermore, PR-39 treatment was seen to increase
nitric oxide levels in the liver in LPS-treated animals. This
appeared to be the result of increased iNOS expression in
liver rather than enhanced systemic production of NO.
We have previously made simultaneous measurements of
NO and pO2 in vivo in mice [18] and demonstrated the
usefulness of EPR oximetry for making measurements of
pO2 from selected tissue regions [20,26]. In the present
study, we observed increased liver NO (observed as an
increase in NO–Fe–(DETC)2 in liver) at 6 h that coincided
with LPS induction of iNOS. Expression of iNOS (mRNA
and protein) is induced in a variety of cell types during
sepsis [27] and is thought to play a critical role in multiple
organ failure [30]. PR-39 significantly increased LPS-
induced iNOS expression in liver but had only a moderate
effect on systemic NOx and no significant affect on circu-
lating HbNO.
We cannot rule out the possibility that reaction of NO
with O2
 was also prevented as a result of the known
inhibitory effects of PR-39 on NADPH-oxidase function.
However, injection of a comparatively large LPS bolus
provides a model in which to study primarily haemody-
namic and physiological dysfunction during a 1–7 h septic
episode. It seems unlikely that PR-39 mediated its effects
via modulation of superoxide production in these studies,
since assessment of oxidative stress to tissue (levels of
thiobarbituric acid reactive substances (TBARS) in liver
tissue and in plasma) or liver damage (levels of serum
aspartate amino transferase (AST)) showed little evidence
for the production of large quantities of reactive oxygen
intermediates like superoxide or the occurrence of oxidative
damage in our model as a result of LPS challenge [28,29]. A
variety of sepsis models are available to specifically inves-
tigate tissue damage and longer term effects of LPS. These
typically involve priming animals with an additional insult
(such as galactosamine or BCG) in order to enhance host
response and bring forward pathophysiological events, usu-
ally observed much later during sepsis. In such a model, we
have previously demonstrated PR-39 reduced oxidative
damage to liver 8–12 h following galactosamine/LPS
[7,21].
Gao et al. [6] reported PR-39 inhibited InBa degradation
and thus inhibited NF-nB-dependent gene expression. We
measured NF-nB DNA binding by EMSA in liver tissue
homogenates and found mice treated with LPS showed an
approximate 18-fold increase in NF-nB binding at 1 h
(compared to controls), typical of early NF-nB activation
following LPS injection. However, an approximate 14-fold
increase was observed in mice treated with PR-39 + LPS
(not significantly different from LPS treatment alone). NF-
nB binding typically declined at 3 and 5 h for both LPS and
with PR-39 + LPS. We can conclude from these experiments
that PR-39 is unlikely to affect expression of iNOS or other
pro-inflammatory proteins mediated via NF-nB. However,
PR-39 significantly increased iNOS expression in liver. PR-
Table 2
Summary of in vivo measurements of pO2 in mouse liver 6 h after treatment







Slurry 44.39F 5.13 11.22F 2.48a 23.58F 9.36a,b




The pO2 experienced by the sinusoidal lumen (slurry) and across the
sinusoidal bed (particles), and the difference in pO2 (slurry particle) are
presented. n= six mice for each treatment group. The data is expressed as
the meanF S.D.
a Represents a significant difference compared to control values
( P< 0.01).
b Represents a significant difference compared to LPS values
( P< 0.01).
c Represents a significant difference between particle and slurry values
within each respective treatment group ( P< 0.001).
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39 administration to septic mice showed an approximate 3-
fold increase in iNOS protein expression (compared to LPS
alone), but did not enhance eNOS protein expression. Mice
treated with PR-39 alone also showed an approximate 1-fold
increase in iNOS protein expression when compared to the
controls. PR-39 may have induced iNOS protein via an
unidentified NF-nB-independent mechanism. For example,
activator protein-1 (AP-1) can activate the human iNOS
promoter in cells stimulated with LPS/IFN-g [31].
We concentrated our in vivo measurements of liver pO2
at the 6 h time point because our previous physiological data
indicated that LPS treatment had a significant impact on
MABP and organ perfusion at this time [18]. LPS treatment
resulted in approximately 75% decrease in pO2 both at
sinusoids and across the hepatic tissue bed. This suggests
that LPS-induced hypoxia in this model was primarily the
result of defective oxygen supply to liver sinusoids.
Decreased sinusoidal perfusion could be due to a number
of mechanisms, including LPS-induced arterio-venous
shunting of blood and microaggregation of platelets and
neutrophils within sinusoidal capillaries [32]. Alternatively,
swelling of Kupffer cells within the liver sinusoids may also
cause reduction in sinusoidal capillary diameter, partially or
completely occluding the sinusoids [33].
We found that PR-39 treatment alleviated the LPS-
induced defect in oxygen delivery to sinusoids (an approx-
imate 53% decrease at the sinusoids compared to 75%,
respectively). The oxygen difference between sinusoids and
across the lobule also increased (20 versus 10 mm Hg in
PR-39 + LPS and LPS groups, respectively, reflecting a 25%
improvement compared to controls), which most likely
reflects the improved delivery of oxygen to sinusoids (also
increased by 25% recorded by Gloxy slurry) and increased
oxygen availability across the lobule. Elevated NO induced
by PR-39 may have reduced sinusoidal blockage by main-
taining sinusoid dilatation, eradicating classic inflammatory
responses, such as leukocyte activation and recruitment in
sinusoids [34] and prevented intravascular coagulation.
In addition, PR-39 apparently preserved hepatic tissue
oxygenation almost to the level of controls (approximately 4
mm Hg reported by gloxy particles). Our data strongly
implicates that improvement in sinusoidal perfusion results
in the normalisation of pO2 at both tissue sites. There are,
however, several other plausible explanations to the main-
tenance of 4 mm Hg at the level of the particle that warrant
further study. The increase in local liver NO in mice
subjected to PR-39 + LPS may have contributed to
decreased mitochondrial respiration [35,36] resulting in
higher pO2 across the liver lobule. PR-39 inhibition of
HIF-1a degradation by the ubiquitin–proteasome system
may also have facilitated enhanced glycolytic capacity and
reduced mitochondrial activity [37].
In conclusion, we have shown, in a mouse model of
endotoxin-induced sepsis, that PR-39 treatment causes a
relative increase in local hepatic NO by influencing iNOS
expression in liver. Our site-selective pO2 measurements
demonstrate that PR-39 preserved sinusoidal perfusion and
lobule oxygenation.
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